Table 2.
Summary of Vaccine Effectiveness Studiesa
| Vaccine | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| BNT162b2 (Pfizer- BioNTech) |
mRNA- 1273 (Moderna) |
AZD1222 (AstraZeneca-Oxford) |
Ad26.COV2.S (Janssen/ Johnson & Johnson) |
Sputnik V (Gamaleya) | CoronaVac (Sinovac) | BBV152 (Bharat) |
BBIBP-CorV (Sinopharm- Beijing) |
All | |
| Total | 86 | 39 | 30 | 16 | 1 | 6 | 1 | 2 | 107 |
| Outcome Type | |||||||||
| Death | 12 | 6 | 5 | 6 | 1 | 4 | 0 | 1 | 21 |
| Severe disease | 38 | 19 | 12 | 10 | 0 | 3 | 0 | 1 | 50 |
| Symptomatic disease | 28 | 12 | 12 | 4 | 0 | 3 | 1 | 0 | 38 |
| Asymptomatic infection | 5 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 9 |
| Any infection | 58 | 25 | 14 | 7 | 1 | 2 | 0 | 1 | 67 |
| Population Type | |||||||||
| General population | 40 | 26 | 15 | 9 | 1 | 2 | 0 | 2 | 45 |
| Health care workers | 18 | 4 | 1 | 1 | 0 | 0 | 1 | 0 | 20 |
| Older adults (≥60 years) | 8 | 0 | 8 | 1 | 0 | 2 | 0 | 0 | 11 |
| Other age groups | 6 | 3 | 3 | 2 | 0 | 0 | 0 | 0 | 7 |
| Contacts of cases | 6 | 2 | 3 | 2 | 0 | 0 | 0 | 0 | 6 |
| LTCF/SNF residents | 5 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 5 |
| Other groups | 6 | 3 | 1 | 1 | 0 | 2 | 0 | 0 | 9 |
| Study Design | |||||||||
| Test-negative case control | 30 | 21 | 13 | 7 | 0 | 3 | 1 | 1 | 42 |
| Traditional case-control | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Prospective cohort | 17 | 4 | 7 | 1 | 0 | 1 | 0 | 0 | 21 |
| Retrospective cohort | 36 | 13 | 9 | 8 | 1 | 2 | 0 | 1 | 41 |
| No. of Doses | |||||||||
| Complete | 76 | 36 | 19 | 16 | 1 | 6 | 1 | 2 | 96 |
| Partial | 44 | 14 | 25 | N/A | 0 | 3 | 1 | 0 | 53 |
| Variants of Concern | |||||||||
| Alpha | 33 | 8 | 17 | 2 | 1 | 0 | 1 | 0 | 35 |
| Beta | 4 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 6 |
| Gamma | 2 | 2 | 3 | 1 | 0 | 1 | 0 | 0 | 5 |
| Delta | 22 | 13 | 9 | 5 | 0 | 1 | 1 | 0 | 29 |
| Omicron | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
Abbreviations: COVID-19, coronavirus disease 2019; LTCF, long-term care facility; N/A, not applicable; SNF, skilled nursing facility.
Number of included studies by COVID-19 vaccine and by outcome, population, study design, number of doses, and variant of concern. No studies reported for other vaccine candidates met our inclusion criteria (see Methods). Details of all the individual studies are included in Supplementary Table S1.